An in-depth look at this medical topic, providing essential context for patients and caregivers.
General Medical Overview
Ocular melanoma (Choroid, Iris): A condition categorized under Nervous System & Ophthalmology.
Uveal (ocular) melanoma is the most common primary intraocular malignancy in adults, arising from melanocytes of the uveal tract (choroid, ciliary body, or iris). Unlike cutaneous melanoma, it is driven by GNAQ/GNA11 mutations rather than BRAF and has distinct biology, treatment, and metastatic patterns. Approximately 50% of patients develop metastatic disease, predominantly to the liver. Gene expression profiling (GEP) classifies tumors as Class 1 (low metastatic risk) or Class 2 (high risk).
Typical Treatment Roadmap
Detection
Symptoms and initial checkup.
Diagnosis
Biopsy and clinical imaging.
Treatment
Therapy (Surgery, Chemo, etc.)
Monitoring
Follow-up and recovery.
Clinical Manifestation (Main Symptoms)
Clinically, the initial presentation of Ocular melanoma (Choroid, Iris) often manifests with Fatigue, Dizziness and Pain.
Advanced Stage Signs (Warning)
Visual symptoms (blurred vision, visual field defect, photopsia), visible iris lesion, and liver metastases (often the first sign of systemic spread, which can occur years after primary treatment).
Diagnostic Procedures
Dilated fundus examination, ocular ultrasound (A and B scan), OCT, fundus autofluorescence, GEP testing (DecisionDx-UM for Class 1 vs 2), chromosome 3 monosomy (high-risk marker), and liver MRI for metastatic screening.
Medical Risk Factors
Fair skin, light eye color, ocular melanocytosis (nevus of Ota), BAP1 germline mutations, and UV exposure (less clearly established than for cutaneous melanoma).
Therapeutic Approach
Eye-preserving: plaque brachytherapy (iodine-125 or ruthenium-106) for small/medium tumors, proton beam radiotherapy. Enucleation for large tumors or poor visual prognosis. Metastatic: tebentafusp (bispecific gp100-directed T-cell engager) — first drug to show survival benefit in metastatic uveal melanoma. Liver-directed therapies (hepatic arterial infusion, isolated hepatic perfusion).
Medical Breakthroughs & Hope
Tebentafusp is the first systemic therapy proven to extend survival in metastatic uveal melanoma — a disease that previously had no effective systemic treatment. Eye-preserving radiation techniques maintain vision and avoid enucleation in most patients.
Prognosis & Efficacy45%
Localized uveal melanoma has 5-year survival of approximately 80-85%. However, 50% of patients eventually develop liver metastases. Metastatic uveal melanoma historically had median survival of 6-12 months, but tebentafusp has improved this to approximately 22 months for HLA-A*02:01 positive patients.
Myth vs. Clinical Reality
Myth / Fiction
All melanomas are treated the same way.
Fact / Reality
Uveal melanoma has completely different biology, mutations, and treatment from cutaneous melanoma. BRAF inhibitors and most melanoma immunotherapy regimens are ineffective.
Myth / Fiction
An eye tumor always requires eye removal.
Fact / Reality
Modern radiation techniques (plaque brachytherapy, proton beam) preserve the eye in the majority of uveal melanoma patients.
Frequently Asked Questions (FAQ)
Is this the same as skin melanoma?
No. Uveal melanoma has completely different driver mutations (GNAQ/GNA11 vs BRAF), metastasizes almost exclusively to the liver, and does not respond to standard melanoma drugs (BRAF inhibitors).
Can my eye be preserved?
Yes, in the majority of cases. Plaque brachytherapy and proton beam radiation effectively treat the tumor while preserving the eye. Useful vision is maintained in many patients.
What is tebentafusp?
A bispecific protein that redirects T-cells to attack melanoma cells expressing gp100. It was the first drug ever to improve survival in metastatic uveal melanoma.
Why does it spread to the liver specifically?
Uveal melanoma cells have a unique tropism for the liver microenvironment. The reasons are not fully understood but may relate to specific homing receptors on the tumor cells.
Can genetic testing predict my risk?
Yes. Gene expression profiling (Class 1 vs 2) and chromosome 3 monosomy testing accurately predict metastatic risk, enabling risk-stratified surveillance.